Pascal Biosciences
  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
  • AGM December 18, 2020
Skip to content
Home / News

News

21Jan 2021

Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit

  • Jan 21, 2021
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, January 21, 2021 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV: PAS) (OTC:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today. Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements of Pascal’s…

Read More

20Jan 2021

Pascal Amends Terms of Non-brokered Private Placement

  • Jan 20, 2021
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, January 19, 2021 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV: PAS) (OTC:BIMUF), a biotechnology company that specializes in cancer drug discovery and development, has amended the terms of the non-brokered private placement (the “Private Placement”)…

Read More

8Dec 2020

Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment

  • Dec 8, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, December 8, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) and SōRSE Technology Corporation (“SōRSE”) have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the…

Read More

10Nov 2020

Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications

  • Nov 10, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, November 10, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the appointment of Mark van der Horst to the position of Vice President of Corporate Communications.   Mr. van…

Read More

3Nov 2020

Pascal Announces Non-Brokered Private Placement

  • Nov 3, 2020
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, November 2, 2020 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX VENTURE: PAS), a biotechnology company that specializes in cancer drug discovery and development, announces a non-brokered private placement (the “Private Placement”) of up to 5,000,000…

Read More

3Nov 2020

Pascal Announces Re-pricing of Shares for Debt Settlement

  • Nov 3, 2020
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, November 2, 2020 - Pascal Biosciences, Inc. ("Pascal" or the"Company") (TSX VENTURE: PAS), a biotechnology company that specializes in cancer drug discovery and development, wishes to announce that it has re-priced the debt settlement agreements with certain…

Read More

23Sep 2020

Pascal Biosciences Confirms Specific Cannabinoids Combat Coronavirus

  • Sep 23, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 23, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19.…

Read More

16Sep 2020

Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceutical Summit

  • Sep 16, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 16, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has been invited to present at the International Cannabinoid Derived Pharmaceutical (ICDP) Summit. Today Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in…

Read More

14Sep 2020

Reuters article on partnership with SōRSE Technology

  • Sep 14, 2020
  • In the News

Our exciting partnership with SōRSE Technology has been featured on an article in Reuters. We invite you to read more here: https://www.reuters.com/article/us-pascal-cancer-sorse/canadas-pascal-biosciences-partners-with-sorse-to-test-cannabis-based-cancer-therapy-idUSKBN2651VC

Read More

14Sep 2020

Pascal Biosciences and SōRSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials

  • Sep 14, 2020
  • Press Releases

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 14, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement (the “Agreement”) to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will…

Read More

Page Navigation

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Recent Posts

  • Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit
  • Pascal Amends Terms of Non-brokered Private Placement
  • Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment
  • Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications
  • Pascal Announces Non-Brokered Private Placement

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • March 2020
  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS, FSE:6PB.F) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Facebook
  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer
  • Legal Notices

© Copyright 2021 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
  • AGM December 18, 2020

‹ › ×